CAR-T Meeting 2025 | CAR-T and cell therapies for glioblastoma
Denis Migliorini, MD, University of Geneva, Geneva, Switzerland, discusses the development of two new clinical cell products targeting overexpressed peptides in glioblastoma (GBM). Dr Migliorini highlights the potential of a CAR-T therapy based on the RNA-based technology targeting PTPRZ1, a phosphatase receptor, and a secreted molecule from the extracellular matrix, which can be targeted by CAR-Ts, and notes that disrupting the interaction between these two molecules may further inhibit the invasiveness of the tumor. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
